CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
A year of adjuvant nivolumab after surgery for high-risk melanoma reduced recurrences more than the previous standard, high-dose ipilimumab, with a quarter of the severe toxicity, making PD-1 blockade the adjuvant standard.
Overview
Phase 3 trial of 906 patients with resected stage IIIB, IIIC or IV melanoma randomised to nivolumab or ipilimumab 10 mg/kg for one year.
Twelve-month recurrence-free survival was 70.5 versus 60.8 percent (hazard ratio 0.65), with grade 3 to 4 treatment-related adverse events in 14.4 versus 45.9 percent; four-year recurrence-free survival was 51.7 versus 41.2 percent, with no overall survival difference.
- Twelve-month recurrence-free survival 70.5 percent vs 60.8 percent; hazard ratio 0.65.
- Grade 3 to 4 adverse events 14.4 percent vs 45.9 percent.
Adjuvant nivolumab (or pembrolizumab) is standard for resected stage III and IV melanoma; ipilimumab is no longer used in the adjuvant setting.
- No placebo arm; the comparison is against an active but toxic agent.
- Overall survival did not differ, probably because of effective therapy at relapse.
Similar pages
not linked directly; found by shared links- TrialCheckMate 915
Shares Stage III melanoma (after surgery), Ipilimumab, Nivolumab.
- Key paperKEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma
Shares Stage III melanoma (after surgery), New England Journal of Medicine.
- PersonJeffrey S. Weber
Shares CheckMate 238, Stage III melanoma (after surgery), Ipilimumab, Nivolumab.
- Key paperMSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma
Shares Stage III melanoma (after surgery), New England Journal of Medicine.
- Key paperCheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Shares Ipilimumab, New England Journal of Medicine, Nivolumab.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Nivolumab.
- Key paperNivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis
Shares Ipilimumab, Nivolumab.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Ipilimumab, Nivolumab.